ApoE基因多态性对阿利西尤单抗调脂疗效影响的分析OA北大核心CSTPCD

Objective To investigate the impact of apolipoprotein E(ApoE)gene polymorphism on the lipid-modifying efficacy of alirocumab.Methods A total of 187 patients with dyslipidemia were retrospectively selected for this study.All patients received alirocumab therapy for 6 months.The patients'ApoE gene polymorphism was determined by genotyping using the Sequenom Mass Array system,and they were divided into risk type genotype E4 group(42 cases),common type genotype E3 group(123 cases),and protective type genotype E2 group(22 cases)based on different genotypes.The lipid levels and occurrence of adverse events before and after treatment were compared among the three groups.Results Among the 187 patients,the allele frequencies of ε2,ε3 and ε4 were 7.49％,78.88％and 13.64％,respectively,and the genotype distribution was in Hardy-Weinberg equilibrium.After treatment,the triglycerides(TG)levels in the E2,E3 and E4 groups were(1.42±0.22),(1.56±0.29)and(1.78±0.37)mmol·L-1,respectively;low-density lipoprotein cholesterol(LDL-C)levels were(1.85±0.19),(2.02±0.25)and(2.23±0.41)mmol·L-1,respectively;apolipoprotein A1(ApoA1)levels were(0.85±0.11),(0.92±0.16)and(1.78±0.37)g·L-1,respectively;total cholesterol(TC)levels were(3.03±0.32),(3.42±0.39)and(3.68±0.45)mmol·L-1,respectively;high-density lipoprotein cholesterol(HDL-C)levels were(1.41±0.32),(1.33±0.26)and(1.19±0.20)mmol·L-1,respectively,with statistically significant differences(all P＜0.05).The overall incidence of adverse events in the E2,E3 and E4 groups were 9.09％,11.38％and 19.05％,respectively,with no statistically significant difference(all P＞0.05).Conclusion Compared to the E3 and E4 subtypes,the E2 subtype has superior lipid-modifying effects,but different subtypes do not affect the safety of drug use in patients.